Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Member, Board of Directors
IAS–USA
Rochelle Belfer Professor in Medicine
Chief, Division of Infectious Diseases
Weill Cornell Medicine
New York, New York

Topics of Professional Interest:
  • Antiretroviral therapy strategies
  • New antiretroviral drugs and targets
  • Structured treatment interruptions (STIs)
Current Professional Summary:

Dr Gulick is a Professor of Medicine, Chief of the Division of Infectious Diseases, Department of Medicine at Weill Medical College of Cornell University in New York City.

Committees and Organizations:
  • Member, Board of Directors, IAS–USA
  • Member, HIV Disease Research Agenda Committee, AIDS Clinical Trials Group
  • Chair, Antiviral Advisory Committee, Food and Drug Administration
  • Member, Scientific Advisory Committee, Cornell General Clinical Research Center
  • Member, University Research Ethics Advisory Committee, Cornell University
  • Co-chair, Forum for Collaborative HIV Research
Honors and Awards:
  • Alpha Omega Alpha, National Medical Honor Society, Columbia College of Physicians and Surgeons
  • Most Scientifically Innovative Presentation, 2nd International Workshop on Salvage Therapy for HIV Infection
  • Companero Award (for commitment to HIV/AIDS research), Latino Commission on AIDS
Education:
  • The Johns Hopkins University, BA Biology (1982)
  • Columbia College of Physicians and Surgeons, MD (1986)
  • Columbia-Presbyterian Medical Center, Residency in Internal Medicine (1986-1989)
  • Beth Israel and Massachusetts General Hospitals, Fellowship in Infectious Disease (1989-1991)
  • Harvard School of Public Health, MPH (1993)
Selected Publications:
  1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
  2. Gulick RM, Mellows JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Jonas L, Meibohm A, Holder D, Schleif WA, Condra JH, Emini EA, Isaacs R, Chodakewitz JA, Richman DD. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100 week follow-up. JAMA. 1998;280:35-41.
  3. Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein DS, Meehan P, Hussey S, Forcht J, Valentine FT. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV infected adults: AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med. 1999;130:510-514.
  4. Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, Sommadossi JP, Currier JS, Smeaton L, Frank I, Caliendo AM, Gerber JG, Tung R, Kuritzkes DR. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis. 1999;179:808-816.
  5. Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS. 2000;14:1591-1600.
  6. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, Valentine FT, McMahon D, Gonzalez C, Jonas L, Emini EA, Chodakewitz JA, Isaacs R, Richman DD. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000;133:35-39.
  7. Gulick RM. Assessing the benefits of antiretroviral therapy. Ann Intern Med. 2000;133:471-473.
  8. Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000;182:1375-1384.
  9. Fletcher CV, Acosta EP, Cheng H, Haubrich R, Fischl M, Raasch R, Mills C, Hu XJ, Katzenstein D, Remmel RP, Gulick RM. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS. 2000;14:2495-2501.
  10. Gulick RM, Smeaton LM, D'Aquila RT, Eron JJ, Currier JS, Gerber JG, Acosta E, Sommadossi JP, Tung R, Snyder S, Kuritzkes DR, Murphy RL. Indinavir, nevirapine, stavudine and lamivudine for HIV-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. J Infect Dis. 2001;183:715-721.

Presentations

The 2017 Ryan White HIV/AIDS Program (RWHAP) Clinical Conference

Improving the Management of HIV Disease®: An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

Advances in the Clinical Management of HIV Disease and Hepatitis C Virus Infection

An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

An Advanced CME Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management